Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-509-8 | CAS number: 7601-54-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- July 11, 2005 - December 30, 2005
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study is conducted to an appropriate guideline and under the conditions of GLP. The reliability has been amended (from reliability 1 to 2) to reflect the use of this study for read across. Read across justification: sodium and potassium orthophosphates. The following substances are considered to be similar enough to facilitate read across for systemic toxicity endpoints: Sodium dihydrogenorthophosphate, CAS: 7558-80-7 Disodium hydrogenorthophosphate, CAS: 7558-79-4 Trisodium orthophosphate, CAS: 7601-54-9 Potassium dihydrogenorthophosphate, CAS: 7778-77-0 Dipotassium hydrogenorthophosphate, CAS: 7758-11-4 Tripotassium orthophosphate, CAS: 7778-53-2 Potassium pentahydrogen bis(phosphate), CAS: 14887-42-4 All members of the group are structurally similar ionic inorganic compounds with the anion only changing by the number of hydrogen atoms to account for changes in charge due to increase in cation numbers. Progression through the group sees an increase in cation number from one to three followed by a change in cation from sodium to potassium and again an increase in number from one to three. Both cations are group 1 alkali metals with the same ionic charge, similar chemical behaviour and both sodium and calcium are essential biological elements. Both the Na+ and the K+ cation have a similar biological function and therefore orthophosphate salts of these types are not considered to differ in their systemic toxicity profile. No members of the group are classified for acute toxicity and generally exhibited no mortalities at the classification limit. Two members of the group are classified for local effects only (i.e. skin/eye irritation) which will not have an impact on the systemic toxicity of the compounds and all are highly water soluble. Read-across between these substances has also been justified for repeated dose toxicity. .
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Dipotassium hydrogenorthophosphate
- EC Number:
- 231-834-5
- EC Name:
- Dipotassium hydrogenorthophosphate
- Cas Number:
- 7758-11-4
- Molecular formula:
- H3O4P.2K
- IUPAC Name:
- Dipotassium hydrogen phosphate
- Details on test material:
- - Name of test material (as cited in study report): Potassium phosphate, dibasic (CAS No. 7758-11-4)
- Physical state: solid (messed colourless powder)
- Analytical purity: 1158906: 99.5%, 1118496:99.6%
- Impurities (identity and concentrations): See Appendix 21 for Certificate of Analysis
- Composition of test material, percentage of components: See Appendix 21 for Certificate of Analysis
- Purity test date: No data
- Lot/batch No.: 1158906, 1118496
- Storage condition of test material: Normal temperature, dehumidify
- Other: pH: 9.2
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Orient Co., Ltd
- Age at study initiation: 7 weeks
- Housing: Stainless steel wire cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 8 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C):21.5 - 25°C
- Humidity (%): 41.8 ± 68.7%
- Air changes (per hr): 10- 15 times per hr
- Photoperiod (hrs dark / hrs light): lighting: 12 hrs per day
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
PREPARATION OF DOSING SOLUTIONS: Solution of test substance was prepared daily by suspending in water for injection after measurement of expected test substances expected consumption. Stability and homogeneity analysis of prepared test substance were not conducted after agreement with sponsor.- Details on mating procedure:
- Mating period was a 2 week period. Males and females were mated at a 1:1 ratio in each cage. Coitus was confirmed by dropping of vaginal plug at every morning and afternoon. Gestation day 0 was determined to be the coitus confirmation day.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 2 weeks before copulation to 4 days after parturition in female rats.
2 weeks before copulation to 2 weeks after copulation in male rats. - Frequency of treatment:
- Daily (number of applications is not clearly defined in study report)
- Details on study schedule:
- No data
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 22 Males and 22 Females in the control and test groups
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: In the preliminary test (R05078-P1, R05078-P2, Biotoxtech Co., Ltd) for dose range findings it was considered that dosing of 1000 mg/kg for 7 days did not have any influence. Therefore, 1,000 mg/kg bw was selected as the dose for the main test.
- Post-exposure recovery period in satellite groups: 2 weeks after termination of administration
- Positive control:
- Not applicable.
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once a day, 30 minutes after mating
- Cage side observations checked in tables 2.1-2.2 were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once a day, 30 minutes after mating
BODY WEIGHT: Yes
- Time schedule for examinations: Female: Once a week during first administration, day 1 of dosing, gestational days 0, 7, 14, 20 and potst-partum days 0, 4 and just before necropsy.
Males: Once a week during first administration and just before necropsy
Bodyweights were not measure during mating period.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day:.Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Female: Food consumption, was measured once a week after first administration involved the day before administration, food and water were supplied in gestational day 0, 6, 13, 19 and postpartum day 0, 3 and residue was measured in the next day.
Male: Food consumption was measured once a week after first administration involved the day. Before administration, food and water were supplied in coitus confirm day and the day before necropsy, residue was measured in the next day.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: before necropsy
- Anaesthetic used for blood collection: Yes (ether anesthesia)
- Animals fasted: Yes (18 hours)
- How many animals: 6 females and 6 males
- Parameters stated in table 10 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: As for haematology
- Animals fasted: Yes (18 hours)
- How many animals: 6 females and 6 males
- Parameters stated in table 11 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: collected during 3-4 hr time period in the day before necropsy.
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters stated in table 9 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: start of dosing, just before mating and the day before necropsy
- Dose groups that were examined: all groups
- Battery of functions tested: sensory activity (SOP/RDT/240), grip strength and motor activity (SOP/RDT/24)
ANALYISIS OF MATING RESULT:
Mating result was calculated from observations in coitus and gestation period, parturition day.
- Mating rate (%) = (No. females confirmed / no. males used in mating) x 100
- Mating period = coitus confirm day – coitus starting day
- Gestation period = postpartum 0 day – gestational 0 day
- male fertility (%) = number of pregnant females/no. males used in mating) x 100
- female fertility (%) = (No. pregnant females/no. females confirmed after coitus) x 100
- parturition rate (%) = (no . females delivering live neonates / no. females confirmed after coitus) x 100 - Postmortem examinations (parental animals):
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera. (see tables 12-15)
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 16 were prepared for microscopic examination and weighed, respectively. The number of corpus lutea verum and implantations were also recorded.- Statistics:
- The Levene’s test was conducted to compare the homogeneity of the variance for the data collected from the examinations of the body weight, food and water consumption, haematology, blood chemistry, organ weight, and body weight and crown lump length of neonates. If the variance is homogenous, one-way ANOVA test was performed and if the results showed significance, Dunnets T-test was conducted to find out significance. If the variance was homogeneity after repeat Levene’s test about transformed data, one-way ANOVA test was carried out and if the results showed significance, Dunnets T-test was conducted to find out significance.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- (See table 1 and Appendix 1-1, 1-2)
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- (See tables 2-1, 2-2 and Appendix 1-1, 1-2, (See figures 3,4,5,6 and Tables 4, 5 and Appendix 3-1, 3-2, 4-1, 4-2)
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- (See tables 2-1, 2-2 and Appendix 1-1, 1-2, (See figures 3,4,5,6 and Tables 4, 5 and Appendix 3-1, 3-2, 4-1, 4-2)
- Organ weight findings including organ / body weight ratios:
- no effects observed
Reproductive function / performance (P0)
- Reproductive performance:
- no effects observed
Details on results (P0)
Mortality was not observed in the control and treatment group.
One case of fur loss at the bilateral forelimb in a male rate in the main experiment group and one case of fur loss at the region under the left ear in a female control group rat were observed.
In addition, one case of fur loss at the bilateral forelimb and abdomen region were observed in 1 female in the main test group. There were no other clinical signs.
BODY WEIGHT AND WEIGHT GAIN
There was no difference between the control and treatment groups, apart from a significant increase (p<0.01) of the females in the main experiment group as compared to the controls on postpartum day 0.
WATER CONSUMPTION AND FOOD INTAKE (if drinking water study)
Food consumption was significantly increase (p<0.05) in the male main experiment group compared to the control group on the 28th day of administration and significantly increased (p<0.01) on the 7th day of administration and gestation day 20 in the females in the main experiment. Significant increase (p<0.05) was on the 28th day of administration in the female recovery group.
Water consumption was significantly decreased (p<0.05) in the female main treatment on the gestational days 0 and 6.
HAEMATOLOGY AND CLINICAL CHEMISTY
In haematological test results, there was no difference between the male control and male main experiment group. Haematoloigcal test result of female main experiment group showed that the total erythrocyte count (p<0.01), haemoglobin concentration (P<0.001) and haematocrit (p<0.05) showed significant decrease and mean cell haemoglobin showed significant increase of female treatment group compared to control. There was no difference between recovery control and treatment group except significant decrease (p<0.05) of mean cell haemoglobin of male treatment group.
In the results of blood biochemical tests, alanine aminotransferase showed a significant increase (p<0.05), potassium showed significant decrease (p<0.05) in the males in the main treatment group. Creatinine, total bilirubin (p<0.05), albumin (p<0.05), phosphorus (p<0.01) and calcium showed significant decreases, cholinesterase showed significant increase (p<0.05) in female main experiment group. There was no difference between the control and treatment groups in each sex recovery group
URINALYSIS
There was no change between control and treatment group.
NEUROBEHAVIOUR
There was in the observation of sensory functions through the auricle, acoustic, corneal and pupilary reflex among the control and experimental groups of both the main experiment and recovery experiment groups.
In traction, rota rod and open field test, Significant increase (p<0.05) in the female main experiment group and significant decrease (P<0.01) in the female recovery group were about the number of squares that animal moved in spontaneous locomotor activity box.
ORGAN WEIGHTS
In the absolute organ weight there was no difference between the control and treatment group except significant increase (p<0.05) of thymus compared to control in male recovery group. In the relative organ weight there was no difference between the control and treatment groups except significant decrease of the heart and liver compared to the control in the female main experimental group.
There was no significant change in the male sex absolute and relative organ weights.
GROSS PATHOLOGY
In the scheduled necropsy on the main experiment group, there was no specific finding in the control and treatment group. In the case of recovery group, there were no specific findings in the control and treatment group except unilateral yellow cyst of caudal epididymis.
HISTOPATHOLOGY: NON-NEOPLASTIC
There were no specific findings in the histopathological tests of six males and six females in the main experiment group and male and female recovery group. In the result of the histopathological tests on the case of unilateral cyst of the caudal epididymis in the recovery group, it was confirmed that the spermatic granuloma observed were cause by accidiential shock causing the epididymal duct to move to the institial tissue.
It was considered that spontaneous reference findings were observed randomly and there was no dose response relation on the cellular infiltration and microgranuloma of liver and cellular infiltration and inorganic matter permeation of the liver in control and treatment groups.
Therefore no findings relating to the test substance were observed in the recovery and treatment groups.
PRE AND POST IMPLANTATION LOSS (Table 17 and Appendix 17)
In the control and treatment group, group pre-implantation loss rates by calculation of numbers of corpus lutea verum and implantation sites were 43.59 and 42.54%. Individual pre-implantation loss rates were 39.96 and 39.99%. Group post-implantation loss rates were 6.82 and 4.76%. Individual pre-implantation loss rates were 7.77 and 4.60%.
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Fertility
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Results: F1 generation
Details on results (F1)
Mean litter sizes (No.) were 12.8 and 13.8, birth rates were 98.5 and 97.3%, postpartum 0 days survival rates were 100%, postpartum 4 days survival rates were 99.5% and 99.1%, sex ratio in postpartum 0 and 4 days body weight and crown lump length. There was no abnormalities about external examination of neonates in control and treatment groups.
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- It is considered that the NOAEL for reproductive parameters of the parent animals (fertility) and the development of neonates is 1000 mg/kg bw because all animals in the control and treatment groups were successful in mating, pregnancy and parturition. No effects on neonatal development were noted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.